ESMO24: First-Line Immunotherapy Combination Improves Overall Survival in HER2-Positive Metastatic G/GEJ Adenocarcinoma
The data positions pembrolizumab in combination with trastuzumab and chemotherapy as a first-line treatment option for HER2-positive metastatic G/GEJ adenocarcinoma, particularly in patients with higher PD-L1 expression.